Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.
Int J Gen Med. 2009 Dec 29;2:263-9. doi: 10.2147/ijgm.s6856.
To review recent advances in the understanding of Graves' ophthalmopathy (GO) pathogenesis as well as discuss current and future medical management strategies.
Interpretive essay.
Literature review and interpretation.
Medical treatment of GO has slowly evolved during the past few decades and has been hampered by a poor understanding of the disease at a cellular and molecular level. Current treatment recommendations and guidelines therefore focus on nonspecific immuno-suppression. Newer classes of treatment agents hold promise to more selectively target underlying cellular and molecular alterations in GO.
Cooperation between individual patients, physicians and between differing medical centers, together with a refined understanding of the pathogenesis of GO, will lead to newer more-effective treatments for the disease and improve patient quality of life.
回顾 Graves 眼病(GO)发病机制研究的最新进展,并讨论当前和未来的医学治疗策略。
阐释性文章。
文献回顾与阐释。
GO 的医学治疗在过去几十年中缓慢发展,其主要障碍是对疾病在细胞和分子水平上的认识不足。因此,目前的治疗建议和指南侧重于非特异性免疫抑制。新型治疗药物具有更有选择性地靶向 GO 中潜在的细胞和分子改变的潜力。
患者、医生以及不同医疗中心之间的合作,以及对 GO 发病机制的深入了解,将为该疾病带来更有效、更新的治疗方法,并改善患者的生活质量。